Evidence map›Paper›PMID 39285067›Full record

ArticleThe AAPS journal2024

Determining the Degree of Sulfo-tag Conjugation to AAV5 Vectors by LC-HRMS and Evaluating the Effects on Antibody Binding Affinity and Bridging Assay Sensitivity.

Yanshan Dai, Xinqun Wu, Xiaowei Sun, Daniel Cohen, Divakar Rajeswaran, Scott Robotham, Shannon Chilewski, Kun Yang, Graham Yearwood, Alexander Kozhich and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yanshan DaiClinical Pharmacology, Pharmacometrics, & Bioanalysis, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA. Yanshan.dai@bms.com.ORCID 0000-0001-5048-7417
Xinqun WuClinical Pharmacology, Pharmacometrics, & Bioanalysis, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Xiaowei SunTranslational Sciences and Diagnostics, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Daniel CohenProtein Sciences, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Divakar RajeswaranProtein Sciences, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Scott RobothamTranslational Sciences and Diagnostics, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Shannon ChilewskiTranslational Sciences and Diagnostics, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Kun YangClinical Pharmacology, Pharmacometrics, & Bioanalysis, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Graham YearwoodTranslational Sciences and Diagnostics, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Alexander KozhichClinical Pharmacology, Pharmacometrics, & Bioanalysis, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.
Vibha JawaClinical Pharmacology, Pharmacometrics, & Bioanalysis, Bristol Myers Squibb Company, Princeton, New Jersey, 08543, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-existing anti-AAV antibodies can be detected using ligand binding-based assay formats. One such format is the MSD-based bridging assay, which uses sulfo-tag-labeled AAV vectors as detection reagents. However, no method has been developed to accurately measure the degree of sulfo-tag labeling on AAV vectors. To fill this gap, we developed a liquid chromatography-high resolution mass spectrometry (LC-HRMS) method to assess the degree of labeling (DoL) of sulfo-tag on AAV5 vectors, enabling the measurement of the DoL on AAV5 at six increasing levels of sulfo-tag challenge ratio. In addition, a Biacore-based assay was used to evaluate the binding affinity between an anti-AAV5 monoclonal antibody and various sulfo-tag labeled AAV5 vectors. The results indicated that increased DoL of sulfo-tag labeling on AAV5 did not compromise the binding affinity.Our study further employed the MSD-bridging assay to detect the binding Signal/Noise (S/N) ratios of four anti-AAV5 monoclonal antibodies (mAbs) to various sulfo-tag-labeled AAV5 vectors. The findings revealed a strong correlation between the degree of sulfo-tag labeling and both the S/N ratios and the sensitivity of MSD bridging assays. This result underscores the importance of optimizing the labeling of detection reagents to enhance assay sensitivity for detecting anti-AAV5 antibodies.

Indexed as

Antibodies, MonoclonalDependovirusGenetic VectorsAnimalsAntibody AffinityChromatography, LiquidHumansMass SpectrometryAntibodies, MonoclonalAAV5 serotypeAdeno-associated virusAnti-AAV5 antibodyBiacoreElectrochemiluminescenceLiquid chromatography-high resolution mass spectrometry (LC-HRMS)Meso-scale discovery (MSD)MSD bridging assay

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.